MID-35

• Myostatin pathway inhibition that blocks the ActRIIB receptor binding site, preventing downstream Smad2/3 phosphorylation and suppression of myogenic gene transcription, thereby enabling skeletal muscle development.
• Selective receptor-site targeting that inhibits myostatin without broadly neutralizing related TGF-β superfamily ligands such as activin A, GDF-11, or BMP9/10, distinguishing it from non-selective inhibitor approaches.
• Proteolytic resistance through D-amino acid composition that confers superior enzymatic stability compared to conventional L-peptide analogs, supporting enhanced in vivo potency across preclinical administration models.

MID-35 is being explored in research related to

• Skeletal muscle growth and lean mass support signals, with muscle weight increase endpoints observed in animal models following intramuscular administration over multi-week study windows.
• Muscle atrophy and cachexia mitigation interest, including models of cancer-associated wasting where MID-35 demonstrated improvements in muscle fiber cross-sectional area, grip strength, and survival in combination protocols.
• Non-invasive delivery and translational research applications, including transdermal iontophoresis delivery models showing muscle-level peptide penetration and gene expression modulation related to muscle growth and atrophy pathways.

Current published research has not identified consistent or concerning adverse effects in animal models. However, the absence of documented side effects does not indicate confirmed safety, and no human toxicity data exists.